↓ Skip to main content

RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA

Overview of attention for article published in Translational Neurodegeneration, November 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#7 of 220)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
4 news outlets
blogs
1 blog
twitter
4 tweeters
patent
1 patent

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
116 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA
Published in
Translational Neurodegeneration, November 2017
DOI 10.1186/s40035-017-0101-9
Pubmed ID
Authors

Sebastian Aguiar, Bram van der Gaag, Francesco Albert Bosco Cortese

Abstract

Huntington's Disease (HD) is a genetically dominant trinucleotide repeat disorder resulting from CAG repeats within the Huntingtin (HTT) gene exceeding a normal range (> 36 CAGs). Symptoms of the disease manifest in middle age and include chorea, dystonia, and cognitive decline. Typical latency from diagnosis to death is 20 years. There are currently no disease-modifying therapies available to HD patients. RNAi is a potentially curative therapy for HD. A popular line of research employs siRNA or antisense oligonucleotides (ASO) to knock down mutant Huntingtin mRNA (mHTT). Unfortunately, this modality requires repeated dosing, commonly exhibit off target effects (OTEs), and exert renal and hepatic toxicity. In contrast, a single AAV-mediated short-hairpin RNA (shRNA) dose can last years with low toxicity. In addition, we highlight research indicating that shRNA elicits fewer OTEs than siRNA when tested head-to-head. Despite this promise, shRNA therapy has been held back by difficulties controlling expression (oversaturating cells with toxic levels of RNA construct). In this review, we compare RNAi modalities for HD and propose novel methods of optimizing shRNA expression and on-target fidelity.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 116 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 39 34%
Student > Master 20 17%
Researcher 12 10%
Student > Ph. D. Student 10 9%
Other 5 4%
Other 8 7%
Unknown 22 19%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 35 30%
Agricultural and Biological Sciences 19 16%
Neuroscience 10 9%
Medicine and Dentistry 9 8%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Other 9 8%
Unknown 28 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 45. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2020.
All research outputs
#565,242
of 17,483,393 outputs
Outputs from Translational Neurodegeneration
#7
of 220 outputs
Outputs of similar age
#20,313
of 419,396 outputs
Outputs of similar age from Translational Neurodegeneration
#3
of 22 outputs
Altmetric has tracked 17,483,393 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 220 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,396 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.